Category Archives: General Cynicism

Et tu Multivitamins–They don’t work either

A large study of women taking vitamins showed no efficacy in preventing cancer or heart disease.

“But the largest study ever conducted in post-menopausal women has found “convincing evidence” that multivitamin use has “little or no influence” on the risk of common cancers, cardiovascular disease or dying from any cause in post-menopausal women.”

“The research involved 161,808 American women, age 50 to 79, who are part of the ongoing Women’s Health Initiative, the largest study of women’s health. A total of 41.5 per cent of the women used multivitamins. The most popular was a multivitamin with minerals.”

“The women were enrolled in the trial between 1993 and 1998. After an average eight years of followup, researchers found no evidence multivitamins either increased or decreased the risk of cancers of the breast (invasive), colon/rectum, endometrium, ovary, kidney, bladder, stomach or lung.”

“They also found no significant effect on the risk of heart attack, stroke and blood clots in the veins.”

What can a person concerned about his/her health do to prevent disease and expect that it will work? At this point the proven interventions are:

1. Eat a well balanced diet. Vitamins appear to be more effective if taken in the form of a healthy diet.

2. Exercise and control your weight.

3. And probably most important, don’t smoke.

Powered by Zoundry Raven

A Corrupt System of Care

This, in the Wall Street Journal, describes the reality of the uninsured and under-insured. Guess who will ultimately pay?

“Hospitals are adopting a policy to improve their finances: making medical care contingent on upfront payments.”

“The bad debt is driven by a larger number of Americans who are uninsured or who don’t have enough insurance to cover medical costs if catastrophe strikes. Even among those with adequate insurance, deductibles and co-payments are growing so big that insured patients also have trouble paying hospitals.”

“Asking patients to pay after they’ve received treatment is “like asking someone to pay for the car after they’ve driven off the lot,” says John Tietjen, vice president for patient financial services at M.D. Anderson. “The time that the patient is most receptive is before the care is delivered.”

Medicynical note: For these patients with cancer it is pay or die. One can only speculate on what happens to those who can’t pay. Is this what we, as a society, desire?

Powered by Zoundry Raven

Litigate to delay

Pay to delay is strategy of pharmaceutical companies whereby the owners of a drug patent pay (bribe?) generic manufactureres to not market generic competition for their patented agent.

“lucrative settlements between generic and branded drugmakers have flourished. According to the FTC, nearly half of all settlements between 2006 and 2007 involved payments to keep low-cost drugs off the market.”

Imagine, our non-system facilitates keeping drug costs high. What a system.

Powered by Zoundry Raven

Mark Dybul’s Removal–inevitable

Mark Dybul by all indications was as effective as an HIV/AIDS coordinator could be working for a narrow minded, religious right agenda driven administration. That being said it appears he compromised too often to be held over in the new administration.

This from Michelle Goldberg in the American Prospect:

“A gay man who had, in the past, donated to Democrats, Dybul seemed to pride himself on his ability to make common cause with conservatives. As global AIDS coordinator in the Bush White House, he often sided with allies like Rick Warren rather than with women’s-health advocates on issues ranging from abstinence to sex-worker outreach to family-planning funding.”

“Thus, while PEPFAR did miraculous things to treat and care for people with HIV — an expensive but relatively uncontroversial undertaking — it missed many opportunities to prevent new infections. Initially, at the administration’s behest, the legislation authorizing PEPFAR earmarked a third of the money dedicated to HIV prevention for abstinence and faithfulness programs, often run by religious groups. With other PEPFAR prevention funds directed toward things like mother-to-child transmission, very little was left over for comprehensive sex education and condom distribution. In fact, in order to fulfill the abstinence earmark, Dybul’s office told those in the field to devote a full two-thirds of the money available for the prevention of sexual transmission of HIV to programs encouraging chastity and fidelity.”

Medicynical note: An effective proponent of ineffective prevention policy is not an automatic reappointment candidate. As noted the abstinence mandate in the Bush/Dybul program corroded the effectiveness of the interventions. Dybul appears to have compromised what might work with the ineffective and scientifically flawed.

I’ve always felt that selling out the AIDS program to the religious right, who previously couldn’t even say the AIDS word, was a travesty. In that Dybul facilitated this sell out he didn’t deserve reappointment.

Powered by Zoundry Raven

Corrupt Practices vs Corruption–Conflicts of Interest

Marcia Angell during and after her tenure as editor of the New England Journal of Medicine has decried pharmaceutical industry practices. Her recent review of three books in the NY Review of books has gotten the attention of industry.

The books were Side Effects: A Prosecutor, a Whistleblower and a Best Selling Antidepressant on trial by Alison Bass, Our Daily Meds: How the Pharmaceutical Companies Transformed themselves into Slick Marketing Machines and Hooked the Nation on Prescription Drugs by Melody Petersen, and Shyness: How Normal Behavior became a Sickness by Christopher Lee.

In the article Angell highlighted the practice of having researchers on payrolls of companies whose products they were evaluating. She called the practice corrupt and urged:

“But there is clearly also a need for the medical profession to wean itself from industry money almost entirely. Although industry-academic collaboration can make important scientific contributions, it is usually in carrying out basic research, not clinical trials, and even here, it is arguable whether it necessitates the personal enrichment of investigators. Members of medical school faculties who conduct clinical trials should not accept any payments from drug companies except research support, and that support should have no strings attached, including control by drug companies over the design, interpretation, and publication of research results.”

Dr. Alvin Shatzberg and his University (Stanford) took issue with calling conflicts of interest a corrupt practice and had an exchange of correspondence with Dr. Angell in the February 26, 2009 issue of NY Review of Books. The major point of Dr. Shatzberg and the University appears to be:

“The exchange of money or other items of value between the medical community and medically related industries should be transparent and limited to payment for legitimate services.”

“As Angell notes, the provision of money and other valuables by pharmaceutical companies to medical schools, medical societies, and individual physicians has been widely accepted for many years. Some of the effects, such as the development of effective new treatments, have been positive. It is good that society and the profession are finally paying attention to the consequences that are negative. But standards-of diagnosis, research, and behavior-change over time. It is unfair to suggest physicians are “corrupt” for activities that were virtually universal when they occurred.”

Dr. Angell replied:

“My article was about the conflicts of interest that permeate medicine, not failures to disclose them. And nowhere did I state or imply that they were unlawful, as Schatzberg’s lawyer charges. My point was that pervasive conflicts of interest corrupt the medical profession, not in a criminal sense, but in the sense of undermining the impartiality that is essential both to medical research and clinical practice.”

Medicynical note: It’s necessary to read the original article to fully appreciate the issues. Medicine in my professional lifetime has compromised itself. Our profession no longer can be relied upon to put the patient’s interest first. We’ve monetarized the system and the choices made have corrupted it.

I’ve always felt that disclosure of a conflict of interest did not help. For example, what does it mean when the author of an article reveals he/she is being paid by and/or has a financial interest in the company whose drug, procedure, or medical device the doctor is evaluating. How much should we rely on the conclusions of an obviously biased source? The practice at best opens the door to doubt and at worst corrupts and irreversibly contaminates them.

Powered by Zoundry Raven

Bredeson NO!!

President Obama is apparently considering Gov. Phil Bredesen as secretary of HHS. The governor however disqualified himself with this quote in the Wall Street Journal:

“Anybody who’s got some real scars and experience is going to have their detractors,” the governor said Monday in an interview with The Wall Street Journal. “People at the White House are smart enough to be able to assess that.” And he took a swipe at his opponents, saying that “advocacy groups don’t matter nearly as much as the pharmaceutical groups, the hospitals, the doctors’ groups. There’s a lot of very powerful interest groups that will play in this thing.” (Medicynical emphasis)

Somehow I can’t imagine a useful HHS secretary who puts pharmaceutical interests above patient advocacy groups. That’s not CHANGE!!!

Powered by Zoundry Raven

Deregulation and Patient Autonomy–two sides of the same coin

Without rules (regulation) banks seek ways to manipulate the system to maximize profits. The current financial mess was facilitated by banks’ ability to make bad loans and then pass the risk to someone else.

In health care we have similar situation. We insist on autonomy for patients (deregulation). It’s in our ethical code that patients and their providers are free to make health care decision that best fit the needs of the patient. Our system of insurance facilitates this by passing the financial ramifications (risk) of this decision on to someone else–insurers and ultimately government health programs.

In the financial system some form of regulation is apparently essential to prevent financial collapses–we’re had several major financial crises related to deregulation over the past 25 years. It appears that Friedman, Milton that is, was wrong and financial markets are unable to regulate themselves without collapsing.

In healthcare we need a similar check on poorly considered treatments. Our system is collapsing. It’s estimated that up to 30% of health care services are unnecessary. Many approaches are overpriced and not cost-effective–that is they have some efficacy but the cost is beyond which any health care system, much less most individual, can afford.

Conservatives believe that by passing costs on to the patient we will force them to make better decisions and the system will self regulate (Medicynical note: as effectively as our financial system? ). They propose health savings accounts and high deductible insurance plans, with an emphasis on patients sharing the cost. Not a bad idea if we all had high incomes and lots of savings. But it’s a fact that the median income in our country is just $50,000/household and most citizens have very limited savings. Believe me, most families cannot afford several thousand dollars/year more in health expenses (deductibles and cost sharing)–above and beyond the several thousand already paid for insurance. In such a system, if implemented, those who become sick and can’t afford their cost sharing will continue to seek care and gravitate, just as now, into the public system. The conservative solution leads to a dead end.

A better approach is more comprehensive health coverage with moderate deductibles but with a system that assesses health technology and advances for efficacy and cost effectiveness. Hopefully when developers of new approaches realize that the system won’t pay exorbitant prices for modest advances, value will become a part of health care.

We literally have to change the culture of medicine.

Powered by Zoundry Raven

The Financial Impact of Cancer on patients

The American Cancer Society and the Kaiser Foundation have published a report on the financial impact of cancer on patients and their families. It notes 5 major issues:

1. “High cost-sharing, caps on benefits leave cancer patients vulnerable. The various types of cost-sharing and limits on benefits found in some insurance plans may quickly lead to high out-of-pocket costs once cancer treatment begins.” Medicynical note Cost sharing does force patients to factor cost into decisions. However, because of the huge expenses to patients and their families, cost sharing may adversely affect the access of some patients to treatment. Thoughtlessly implemented cost sharing is a blunt instrument that is not appropriate as a strategy to limit costs.

2. “Those with employer-sponsored coverage may not be protected from catastrophically high health care costs if they become too sick to work.” Medicynical note: Our system is carefully designed to eliminate and/or downgrade patient insurance coverage if a person becomes so sick they can’t work. Marquis de Sade could not have done better.

3. “Cancer patients and survivors are often unable to find adequate and affordable coverage in the individual market.” Medicynical Note: Rating individuals rather than populations, a long standing goals of insurers, guarantees profits while undermining care. When you become sick, insurance rates increase to the point where you can’t afford it. We have a carefully calculated money making system for insurers, not a benevolent caring health care system.

4. “High-risk insurance pools are not available to all cancer patients, and some find the premiums difficult to afford.” Medicynical note: More of the same. We have more safeguards for insurers than patients.

5. “Waiting periods, strict restrictions on eligibility, or delayed application for public programs can leave people who are too ill to work without an affordable insurance option.” Medicynical note: Ditto. Even where our system has programs to fill gaps they are designed to limit access.

Powered by Zoundry Raven

Daschle NO!

It appears that Tom Daschle is not the right person to reinvigorate anything. This from the Times:

“he had failed to pay $128,000 in taxes on the car and driver Mr. Hindery’s firm provided him, threatening to derail his confirmation as secretary of health and human services.”

“Beyond the ramifications for Mr. Daschle’s ascent to the cabinet, the disclosures about Mr. Hindery and the many clients Mr. Daschle advised on public policy offers a new window into how Washington works. It shows how in just four years an influential former senator was able to make $5 million and live a lavish lifestyle by dint of his name, connections and knowledge of the town’s inner workings.”

More from Rolling Stone’s Matt Tabbi:

“Regarding Daschle, remember, we’re talking about a guy who not only was a consultant for one of the top health-care law firms in the country, but a board member of the Mayo Clinic (a major recipient of NIH grants) and the husband of one of America’s biggest defense lobbyists – wife Linda Hall lobbies for Lockheed-Martin and Boeing. Does anyone really think that this person is going to come up with a health care proposal that in any way cuts into the profits of the major health care companies?”

There’s more in Glenn Greenwald’s column in Salon. And more in this NY times editorial.

Daschle doesn’t pass the smell test. We need someone with fewer industry ties and a genuine commitment to change.

Powered by Zoundry Raven

Wellpoint typifies our failed health insurance system

Bloomberg’s comments about Wellpoint amplify the faults of our insurance system. Remember we’re not talking about a company supplying widgets.

“WellPoint recorded $543.2 million in pretax investment losses in the fourth quarter and $1.1 billion for the year. Mistakes in setting rates, which the company blamed on computer errors, also hurt earnings. The company additionally faulted computer foul-ups for keeping elderly customers from getting drugs, leading the government to block WellPoint this month from adding Medicare customers. Layoffs by customers fed a decline of 288,000 in enrollment in the quarter.”

Wellpoint appears to have misplaced a billion dollars. What in the world are they investing in that gave them this magnitude of loss? Remember they are supposed to be holding this money in a safe place to be able to pay for our health care–and their bonuses! (they only pay 83% of revenues to patients)

After being in business for over 50 years Wellpoint still makes major errors, in their favor of course, when it comes to paying for care. In this case they blocked elderly patients from receiving their medications and overcharged others. Amazing.

Lastly, and this is not Wellpoint’s problem, when people get sick and can’t work and they lose their insurance. What happens to these people? They stop seeking preventive medical services and in emergent situations seek care through ERs and public clinics.

Guess who ultimately pays? This goes away with a national health scheme.

Powered by Zoundry Raven